{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:39:49Z","timestamp":1792629589704,"version":"4.5.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100010751","name":"Indian Rheumatology Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy of cyclophosphamide (IV CYC), mycophenolate mofetil (MMF), and tacrolimus (TAC), as induction treatment for lupus nephritis (LN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This randomized, open-label, non-inferiority, active-controlled three-arm study included children and adult patients aged \u226510 years with clinical or biopsy-proven LN over a period of 1 year. Patients were randomized in a 1:1:1 ratio to receive IV CYC (0.5-0.75\u00a0g\/m\n                      <jats:sup>2<\/jats:sup>\n                      monthly for 6 doses), MMF (2-3\u00a0g\/day), or TAC (0.08-1\u00a0mg\/kg\/day). The primary outcome was the proportion of patients achieving renal response [complete (CR) or partial (PR)] at week 24 and secondary outcomes included the proportion of CR, PR, change in complements, anti-dsDNA antibody, and 24-hour urine protein levels, SLEDAI-2K and renal-SLEDAI scores from baseline to week 24. Serum CXCL10 was assessed at baseline and follow-up. Intention-to-treat analysis was performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      82 patients (94% females; median age 27.5 years) were randomized to receive IV CYC (28), MMF (27), and TAC (27). At 24 weeks, the renal response rates were 53.5%, 66.6%, and 62.9% in IV CYC, MMF, and, TAC groups, respectively. The lower limit of the confidence interval for the difference in renal response at 24 weeks between treatment groups was less than 20% (non-inferiority margin) (\n                      <jats:italic>p<\/jats:italic>\n                      = .58). Serum CXCL10 reduced significantly post-treatment in all three groups (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; .001). Three patients in the IV CYC group and one patient in TAC group died due to serious infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TAC was non-inferior compared to IV CYC and MMF for LN as induction therapy, with a comparable safety profile during the study period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09612033251361560","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T07:46:10Z","timestamp":1752479170000},"page":"1211-1220","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative efficacy of intravenous cyclophosphamide, mycophenolate mofetil, and tacrolimus as induction therapy for lupus nephritis: A randomized controlled open-label trial"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5050-4976","authenticated-orcid":false,"given":"Alekhya","family":"Amudalapalli","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmi Ranjan","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlesha","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhichandra","family":"Maddineni","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Nagar","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshani","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhish","family":"Gadde","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Buvanahalli Venkatshappa","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanth","family":"Madan","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gargi","family":"Sasmal","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8321-8117","authenticated-orcid":false,"given":"Pradeepta Sekhar","family":"Patro","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences &amp; SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05780616"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev311"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31827f4ee3"},{"issue":"2","key":"e_1_3_8_6_2","first-page":"179","article-title":"2024 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"83","author":"Fanouriakis A","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, et al. 2024 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2024; 83(2): 179\u2013190.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.13.59"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex220"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008101028"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr484"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10461"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-3995-3"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009408"},{"issue":"5","key":"e_1_3_8_16_2","first-page":"692","article-title":"Tacrolimus versus cyclophosphamide for induction treatment of lupus nephritis: a randomized controlled trial and long-term follow-up","volume":"81","author":"Zheng Z","year":"2022","unstructured":"Zheng Z, Tian S, Li X, et al. Tacrolimus versus cyclophosphamide for induction treatment of lupus nephritis: a randomized controlled trial and long-term follow-up. Ann Rheum Dis 2022; 81(5): 692\u2013699.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_8_17_2","first-page":"2925","article-title":"Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis","volume":"14","author":"Zhou T","year":"2020","unstructured":"Zhou T, Lin S, Yang S, et al. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Dev Ther 2020; 14: 2925\u20132937.","journal-title":"Drug Des Dev Ther"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206456"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.125"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310371154"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2881"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030491"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24803"},{"issue":"3","key":"e_1_3_8_24_2","first-page":"301","article-title":"Serum CXCL10 as a potential biomarker of lupus nephritis: a retrospective study","volume":"33","author":"Wang Y","year":"2024","unstructured":"Wang Y, Liu X, Zhang H, et al. Serum CXCL10 as a potential biomarker of lupus nephritis: a retrospective study. Lupus 2024; 33(3): 301\u2013308.","journal-title":"Lupus"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1202-z"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000584"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.318"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160041"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251361560","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033251361560","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251361560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:29:11Z","timestamp":1777678151000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033251361560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/09612033251361560"],"URL":"https:\/\/doi.org\/10.1177\/09612033251361560","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}